Lifecore Biomedical, Inc. (LFCR)
USD 6.18
(2.32%)
USD 6.18
(2.32%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 219.8 Million USD | -14.47% |
| 2023 | 256.99 Million USD | 37.21% |
| 2022 | 187.29 Million USD | -37.6% |
| 2021 | 300.14 Million USD | -3.26% |
| 2020 | 310.26 Million USD | 24.63% |
| 2019 | 248.94 Million USD | 63.63% |
| 2018 | 152.14 Million USD | 17.16% |
| 2017 | 129.85 Million USD | -0.96% |
| 2016 | 131.12 Million USD | 3.77% |
| 2015 | 126.35 Million USD | 16.07% |
| 2014 | 108.86 Million USD | -1.51% |
| 2013 | 110.52 Million USD | -12.37% |
| 2012 | 126.13 Million USD | 83.91% |
| 2011 | 68.58 Million USD | 1.28% |
| 2010 | 67.72 Million USD | 163.82% |
| 2009 | 25.67 Million USD | -25.75% |
| 2008 | 34.57 Million USD | 18.02% |
| 2007 | 29.29 Million USD | -9.04% |
| 2006 | 32.2 Million USD | 21.3% |
| 2005 | 26.54 Million USD | -11.23% |
| 2004 | 29.9 Million USD | -21.16% |
| 2003 | 37.93 Million USD | -24.53% |
| 2002 | 50.26 Million USD | -27.42% |
| 2001 | 69.24 Million USD | -13.23% |
| 2000 | 79.81 Million USD | 796.74% |
| 1999 | 8.9 Million USD | 2.3% |
| 1998 | 8.7 Million USD | -40.41% |
| 1997 | 14.6 Million USD | 711.11% |
| 1996 | 1.8 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 FY | 219.8 Million USD | -14.47% |
| 2024 Q2 | 203.47 Million USD | -7.12% |
| 2024 Q4 | 219.8 Million USD | 17.66% |
| 2024 Q3 | 186.8 Million USD | -8.19% |
| 2024 Q1 | 219.06 Million USD | -14.76% |
| 2023 Q4 | 256.99 Million USD | 27.26% |
| 2023 FY | 256.99 Million USD | 37.21% |
| 2023 Q1 | 188.73 Million USD | -4.53% |
| 2023 Q2 | 204.9 Million USD | 8.57% |
| 2023 Q3 | 201.94 Million USD | -1.44% |
| 2022 Q1 | 251.75 Million USD | -16.12% |
| 2022 Q3 | 181.51 Million USD | -31.74% |
| 2022 Q4 | 197.69 Million USD | 8.92% |
| 2022 Q2 | 265.92 Million USD | 5.63% |
| 2022 FY | 187.29 Million USD | -37.6% |
| 2021 Q3 | 305.19 Million USD | 5.16% |
| 2021 FY | 300.14 Million USD | -3.26% |
| 2021 Q1 | 285.02 Million USD | -8.14% |
| 2021 Q2 | 290.22 Million USD | 1.82% |
| 2021 Q4 | 300.14 Million USD | -1.66% |
| 2020 Q2 | 300.92 Million USD | 7.02% |
| 2020 FY | 310.26 Million USD | 24.63% |
| 2020 Q4 | 310.26 Million USD | 2.6% |
| 2020 Q3 | 302.39 Million USD | 0.49% |
| 2020 Q1 | 281.19 Million USD | 12.95% |
| 2019 FY | 248.94 Million USD | 63.63% |
| 2019 Q1 | 149.52 Million USD | -1.72% |
| 2019 Q2 | 158.08 Million USD | 5.73% |
| 2019 Q4 | 248.94 Million USD | 7.53% |
| 2019 Q3 | 231.51 Million USD | 46.46% |
| 2018 Q2 | 146.59 Million USD | 7.95% |
| 2018 Q1 | 135.79 Million USD | 4.58% |
| 2018 Q4 | 152.14 Million USD | 12.13% |
| 2018 FY | 152.14 Million USD | 17.16% |
| 2018 Q3 | 135.68 Million USD | -7.44% |
| 2017 Q2 | 121.79 Million USD | -3.96% |
| 2017 Q1 | 126.82 Million USD | -3.28% |
| 2017 Q4 | 129.85 Million USD | 6.44% |
| 2017 FY | 129.85 Million USD | -0.96% |
| 2017 Q3 | 121.99 Million USD | 0.17% |
| 2016 FY | 131.12 Million USD | 3.77% |
| 2016 Q2 | 134.43 Million USD | 13.37% |
| 2016 Q1 | 118.57 Million USD | -6.16% |
| 2016 Q3 | 122.07 Million USD | -9.2% |
| 2016 Q4 | 131.12 Million USD | 7.41% |
| 2015 Q1 | 118.4 Million USD | 8.77% |
| 2015 Q4 | 126.35 Million USD | 1.24% |
| 2015 Q2 | 129.99 Million USD | 9.78% |
| 2015 FY | 126.35 Million USD | 16.07% |
| 2015 Q3 | 124.8 Million USD | -3.99% |
| 2014 Q4 | 108.86 Million USD | 1.6% |
| 2014 Q3 | 107.14 Million USD | -4.33% |
| 2014 FY | 108.86 Million USD | -1.51% |
| 2014 Q2 | 111.99 Million USD | 6.29% |
| 2014 Q1 | 105.36 Million USD | -4.67% |
| 2013 Q3 | 108.31 Million USD | -1.85% |
| 2013 Q2 | 110.35 Million USD | -2.14% |
| 2013 Q1 | 112.76 Million USD | -10.6% |
| 2013 FY | 110.52 Million USD | -12.37% |
| 2013 Q4 | 110.52 Million USD | 2.04% |
| 2012 Q1 | 67.55 Million USD | -1.51% |
| 2012 Q3 | 61.93 Million USD | -7.55% |
| 2012 Q4 | 126.13 Million USD | 103.65% |
| 2012 FY | 126.13 Million USD | 83.91% |
| 2012 Q2 | 66.99 Million USD | -0.83% |
| 2011 Q2 | 69.05 Million USD | -1.43% |
| 2011 Q3 | 67.38 Million USD | -2.41% |
| 2011 FY | 68.58 Million USD | 1.28% |
| 2011 Q4 | 68.58 Million USD | 1.78% |
| 2011 Q1 | 70.05 Million USD | 3.44% |
| 2010 Q3 | 25.77 Million USD | -7.76% |
| 2010 Q1 | 33.56 Million USD | 27.6% |
| 2010 FY | 67.72 Million USD | 163.82% |
| 2010 Q2 | 27.94 Million USD | -16.74% |
| 2010 Q4 | 67.72 Million USD | 162.73% |
| 2009 Q3 | 25.11 Million USD | -12.12% |
| 2009 Q2 | 28.57 Million USD | -10.1% |
| 2009 Q4 | 26.3 Million USD | 4.73% |
| 2009 FY | 25.67 Million USD | -25.75% |
| 2009 Q1 | 31.78 Million USD | -8.05% |
| 2008 FY | 34.57 Million USD | 18.02% |
| 2008 Q1 | 29.48 Million USD | 0.66% |
| 2008 Q2 | 26.2 Million USD | -11.14% |
| 2008 Q4 | 34.57 Million USD | 35.93% |
| 2008 Q3 | 25.43 Million USD | -2.93% |
| 2007 Q4 | 29.29 Million USD | 3.39% |
| 2007 Q2 | 37.74 Million USD | 39.27% |
| 2007 FY | 29.29 Million USD | -9.04% |
| 2007 Q3 | 28.33 Million USD | -24.94% |
| 2007 Q1 | 27.1 Million USD | -15.85% |
| 2006 Q3 | 39.38 Million USD | 7.84% |
| 2006 Q2 | 36.52 Million USD | 43.27% |
| 2006 FY | 32.2 Million USD | 21.3% |
| 2006 Q4 | 32.2 Million USD | -18.23% |
| 2006 Q1 | 25.49 Million USD | -3.97% |
| 2005 Q1 | 30.94 Million USD | 3.48% |
| 2005 FY | 26.54 Million USD | -11.23% |
| 2005 Q4 | 26.54 Million USD | -18.01% |
| 2005 Q3 | 32.38 Million USD | -4.02% |
| 2005 Q2 | 33.73 Million USD | 9.02% |
| 2004 Q1 | 32.35 Million USD | -13.88% |
| 2004 FY | 29.9 Million USD | -21.16% |
| 2004 Q3 | 37.76 Million USD | -3.21% |
| 2004 Q2 | 39.02 Million USD | 20.6% |
| 2004 Q4 | 29.9 Million USD | -20.82% |
| 2003 Q4 | 37.56 Million USD | -22.41% |
| 2003 FY | 37.93 Million USD | -24.53% |
| 2003 Q3 | 48.42 Million USD | -3.66% |
| 2003 Q2 | 50.26 Million USD | -3.42% |
| 2003 Q1 | 52.04 Million USD | -6.48% |
| 2002 FY | 50.26 Million USD | -27.42% |
| 2002 Q2 | 69.24 Million USD | -6.29% |
| 2002 Q3 | 75.05 Million USD | 8.39% |
| 2002 Q1 | 73.9 Million USD | 0.67% |
| 2002 Q4 | 55.64 Million USD | -25.86% |
| 2001 Q1 | 74.64 Million USD | 11.86% |
| 2001 FY | 69.24 Million USD | -13.23% |
| 2001 Q4 | 73.4 Million USD | -8.49% |
| 2001 Q2 | 79.81 Million USD | 6.92% |
| 2001 Q3 | 80.21 Million USD | 0.51% |
| 2000 Q1 | 6.2 Million USD | -7.46% |
| 2000 FY | 79.81 Million USD | 796.74% |
| 2000 Q3 | 68.4 Million USD | 668.54% |
| 2000 Q2 | 8.9 Million USD | 43.55% |
| 2000 Q4 | 66.73 Million USD | -2.44% |
| 1999 Q3 | 13.4 Million USD | 54.02% |
| 1999 Q4 | 6.7 Million USD | -50.0% |
| 1999 Q1 | 2.8 Million USD | -24.32% |
| 1999 Q2 | 8.7 Million USD | 210.71% |
| 1999 FY | 8.9 Million USD | 2.3% |
| 1998 Q2 | 14.6 Million USD | 21.67% |
| 1998 Q4 | 3.7 Million USD | -65.09% |
| 1998 Q3 | 10.6 Million USD | -27.4% |
| 1998 FY | 8.7 Million USD | -40.41% |
| 1998 Q1 | 12 Million USD | -6.25% |
| 1997 Q3 | 1.6 Million USD | -11.11% |
| 1997 Q1 | 1.5 Million USD | -25.0% |
| 1997 Q2 | 1.8 Million USD | 20.0% |
| 1997 Q4 | 12.8 Million USD | 700.0% |
| 1997 FY | 14.6 Million USD | 711.11% |
| 1996 Q4 | 2 Million USD | 0.0% |
| 1996 FY | 1.8 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alvotech | 1.88 Billion USD | 88.325% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 76.811% |
| Journey Medical Corporation | 56.49 Million USD | -289.033% |
| Dynavax Technologies Corporation | 375.02 Million USD | 41.39% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | -60.589% |
| PainReform Ltd. | 2.69 Million USD | -8067.967% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -3480.038% |
| SCYNEXIS, Inc. | 55.45 Million USD | -296.393% |
| Silver Spike Investment Corp. | 3 Million USD | -7202.736% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -3480.038% |
| Bright Green Corporation | 6.43 Million USD | -3314.05% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 66.737% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | -34.102% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 53.4% |
| Alpha Teknova, Inc. | 38.55 Million USD | -470.154% |
| Embecta Corp. | 2.03 Billion USD | 89.205% |
| Safety Shot Inc | 3.89 Million USD | -5547.418% |
| Procaps Group, S.A. | 462.06 Million USD | 52.431% |
| Cosmos Health Inc. | 30.25 Million USD | -626.551% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -2290.011% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 68.79% |
| Theratechnologies Inc. | 98.63 Million USD | -122.833% |
| Harrow Health, Inc. | 241.75 Million USD | 9.081% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -2410.279% |
| Biofrontera Inc. | 23.13 Million USD | -849.911% |
| DURECT Corporation | 30.4 Million USD | -622.884% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 54.909% |
| Cronos Group Inc. | 43.73 Million USD | -402.56% |
| OptiNose, Inc. | 194.33 Million USD | -13.104% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 73.109% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -353.71% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -947.758% |
| Organogenesis Holdings Inc. | 181.36 Million USD | -21.194% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -5726.94% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -318.537% |
| Radius Health, Inc. | 804.29 Million USD | 72.672% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -1498.042% |
| ProPhase Labs, Inc. | 42.54 Million USD | -416.642% |
| Phibro Animal Health Corporation | 725.54 Million USD | 69.705% |
| Procaps Group S.A. | 462.06 Million USD | 52.431% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -1467.537% |
| Viatris Inc. | 27.21 Billion USD | 99.192% |
| Rockwell Medical, Inc. | 30.88 Million USD | -611.741% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -143.198% |
| SIGA Technologies, Inc. | 57.97 Million USD | -279.114% |
| Tilray Brands, Inc. | 892.11 Million USD | 75.362% |
| Shineco, Inc. | 47.6 Million USD | -361.748% |
| PetIQ, Inc. | 645.22 Million USD | 65.935% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -100031.2% |
| Incannex Healthcare Limited | 5.83 Million USD | -3670.154% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 78.438% |
| Alimera Sciences, Inc. | 107.35 Million USD | -104.743% |
| Assertio Holdings, Inc. | 148.41 Million USD | -48.097% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -11493.041% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -931.161% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -3028.38% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -2488.766% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | -26.768% |
| Hempacco Co., Inc. | 18.82 Million USD | -1067.757% |
| Talphera, Inc. | 6.29 Million USD | -3394.436% |
| Alvotech | 1.88 Billion USD | 88.325% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | -27.346% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 73.685% |
| Currenc Group, Inc. | 177.67 Million USD | -23.709% |
| Kamada Ltd. | 109.96 Million USD | -99.876% |
| Indivior PLC | 1.95 Billion USD | 88.735% |
| Evoke Pharma, Inc. | 9.64 Million USD | -2178.173% |
| Flora Growth Corp. | 17.22 Million USD | -1176.275% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -2488.766% |
| Evolus, Inc. | 209.68 Million USD | -4.823% |
| HUTCHMED (China) Limited | 536.38 Million USD | 59.022% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 74.837% |
| Akanda Corp. | 12.66 Million USD | -1634.959% |